Showing 1,841 - 1,860 results of 4,956 for search 'significant ((((((shape decrease) OR (step decrease))) OR (mean decrease))) OR (small decrease))', query time: 0.52s Refine Results
  1. 1841

    Baseline characteristics of the study sample<sup>β</sup>μ. by Osama Mohamed Ibrahim (12006954)

    Published 2024
    “…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”
  2. 1842

    The flow diagram of the study (CONSORT, 2010). by Osama Mohamed Ibrahim (12006954)

    Published 2024
    “…Pharmacists in Active Group A (37.2%) and Active Group B (32.3%) most commonly intervened by recommending the cessation of medication, while the most common intervention in the Control Group was recommending a decrease in dose (29.8%). The mean cost reduction per patient was highest in Active Group A (31.3 ±11.8 $), followed by Active Group B (20.8 ±8.6 $) and the Control Group (19.6 ±9.5 $). …”
  3. 1843

    Transcript response differences between T1R and LEP patients for GO terms, KEGG or Reactome pathways that showed significant enrichment for both the LEP and T1R groups. by Wilian Correa-Macedo (11813183)

    Published 2024
    “…(<b>C</b>) Heatmap for all DET of the GO term “inflammatory response”. The mean Log<sub>2</sub>FC for all DET was retrieved for each group and ordered by decreasing values of the LEP group. …”
  4. 1844

    Supplementary file 1_Potential interactions between traditional Chinese medicine and osimertinib: a Case Report.docx by Min Zhang (111999)

    Published 2025
    “…<p>Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, played a crucial role in the treatment of EGFR-mutated non-small cell lung cancer. This case firstly reported a case of drug-drug interaction between traditional Chinese medicine (TCM) and osimertinib. …”
  5. 1845

    Image 1_Boys born with hypospadias and fetal growth restriction exhibit shorter anogenital distances: a retrospective cross-sectional study.tif by Wenfeng Pan (8726820)

    Published 2025
    “…Prematurity showed no significant association with AGDs.</p>Conclusion<p>Boys with hypospadias and FGR exhibit significantly shorter AGDs, with more severe hypospadias and SGA showing the strongest associations. …”
  6. 1846
  7. 1847
  8. 1848
  9. 1849
  10. 1850
  11. 1851
  12. 1852
  13. 1853
  14. 1854
  15. 1855
  16. 1856
  17. 1857
  18. 1858
  19. 1859
  20. 1860